EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Incyte's Enterprise Value is $13,781 Mil.
Incyte's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $632 Mil. Therefore, Incyte's EV-to-EBIT for today is 21.81.
The historical rank and industry rank for Incyte's EV-to-EBIT or its related term are showing as below:
INCY'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8534.85 Med: -12.67 Max: 1569.17
Current: 21.72
During the past 13 years, the highest EV-to-EBIT of Incyte was 1569.17. The lowest was -8534.85. And the median was -12.67.
INCY's EV-to-EBIT is ranked worse than 69.96% of 486
companies
in the Biotechnology industry
Industry Median: 7.36
vs INCY: 21.72
The historical data trend for Incyte's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Incyte Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-EBIT
-61.77
104.03
34.42
-75.37
24.33
Incyte Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-EBIT
40.54
20.89
24.33
26.28
22.43
Competitive Comparison
For the Biotechnology subindustry, Incyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, Incyte's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Incyte's EV-to-EBIT falls into.
Incyte's current Enterprise Value is $13,781 Mil.
Incyte's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $632 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (NAS:INCY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Incyte's Enterprise Value for the quarter that ended in Jun. 2022 was $14,177 Mil.
Incyte's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $632 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Incyte's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.27(0.36%) Volume: 973,875 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:INCY has been successfully added to your 
